Title:
COMBINATION AND USES AND TREATMENTS THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/003150
Kind Code:
A3
Abstract:
Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.
More Like This:
| JP2012526054 | Heterocyclic substituted diphenylurea derivatives and their uses |
| WO/2006/082952 | AMIDE COMPOUND |
| WO/2024/078553 | METHOD FOR TREATING PNEUMOCONIOSIS |
Inventors:
CAMPBELL KENNETH CHURCHILL (GB)
DELAET URBAIN ALFONS C (BE)
GUAQUIÈRE JULIETTE SEGOLÈNE (GB)
LAUGHERY THOMAS (US)
LIMET DOMINIQUE J (GB)
POTTAGE JOHN C (US)
RENOU LUDOVIC SYLVAIN MARC (GB)
SCOTT TREVOR R (US)
SEILER CHRISTIAN (GB)
WOODWARD MARY (GB)
GOODRICH JAMES M
DELAET URBAIN ALFONS C (BE)
GUAQUIÈRE JULIETTE SEGOLÈNE (GB)
LAUGHERY THOMAS (US)
LIMET DOMINIQUE J (GB)
POTTAGE JOHN C (US)
RENOU LUDOVIC SYLVAIN MARC (GB)
SCOTT TREVOR R (US)
SEILER CHRISTIAN (GB)
WOODWARD MARY (GB)
GOODRICH JAMES M
Application Number:
PCT/IB2018/054769
Publication Date:
February 21, 2019
Filing Date:
June 27, 2018
Export Citation:
Assignee:
VIIV HEALTHCARE CO (US)
JANSSEN SCIENCES IRELAND UNLIMITED CO (IE)
JANSSEN SCIENCES IRELAND UNLIMITED CO (IE)
International Classes:
A61K31/505; A61K31/513; A61K31/675
Domestic Patent References:
| WO2015140569A1 | 2015-09-24 | |||
| WO2016016279A1 | 2016-02-04 |
Foreign References:
| US20160067255A1 | 2016-03-10 |
Other References:
"ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy; First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine", GSK, 6 May 2015 (2015-05-06), XP055576575
ANONYMOUS: "JULUCA™ (dolutegravir sodium-rilpivirine hydrochloride) oral tablet (cont.) ", PHARMACY COVERAGE GUIDELINES, 18 January 2018 (2018-01-18), XP009518219
ANONYMOUS: "JULUCA™ (dolutegravir sodium-rilpivirine hydrochloride) oral tablet (cont.) ", PHARMACY COVERAGE GUIDELINES, 18 January 2018 (2018-01-18), XP009518219
Download PDF: